ACTIVITY OF CEFEPIME AGAINST CEFTAZIDIME-RESISTANT GRAM-NEGATIVE BACILLI USING LOW AND HIGH INOCULA

被引:35
作者
JOHNSON, CC [1 ]
LIVORNESE, L [1 ]
GOLD, MJ [1 ]
PITSAKIS, PG [1 ]
TAYLOR, S [1 ]
LEVISON, ME [1 ]
机构
[1] DEPT VET AFFAIRS,PHILADELPHIA,PA 19104
关键词
D O I
10.1093/jac/35.6.765
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Cefepime is a broad-spectrum cephalosporin that is reported to have enhanced activity against ceftazidime-resistant Gram-negative bacilli. In this study the effects of varying inoculum size on in-vitro susceptibility to cefepime and other selected antimicrobial agents were determined by agar dilution MICs and in time-kill studies. Among strains of Pseudomonas aeruginosa (n = 55) and Enterobacter spp (n = 56) that had previously been identified as ceftazidime-resistant, 73% and 96% were susceptible to cefepime (MIC less than or equal to 16 mg/L), respectively, when tested with an inoculum of 10(4) cfu. However, with an inoculum of 10(7) cfu, 98% and 100% of strains were resistant, respectively. Furthermore, the bactericidal activity of cefepime against ceftazidime-resistant isolates was also inoculum-dependent. In time-kill studies, bactericidal action was obtained only at the lowest concentration of organisms (10(4) cfu/mL). beta-Lactamase extracted from an isolate of P. aeruginosa that demonstrated an inoculum effect had a lower affinity for cefepime than for ceftazidime. Overall, cefepime proved to be more resistant to hydrolysis by the beta-lactamase. However, differences in kinetics of the beta-lactamase against cefepime or ceftazidime do not appear to be of consequence in determining susceptibility of P. aeruginosa and Enterobacter spp. at high bacterial densities, since most strains with chromosomally/mediated beta-lactamase are highly resistant.
引用
收藏
页码:765 / 773
页数:9
相关论文
共 26 条
[1]   INVITRO STUDIES OF BMY-28142, A NEW BROAD-SPECTRUM CEPHALOSPORIN [J].
BODEY, GP ;
HO, DH ;
LEBLANC, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (02) :265-269
[2]   COMPARATIVE ACTIVITY OF CEFEPIME, ALONE AND IN COMBINATION, AGAINST CLINICAL ISOLATES OF PSEUDOMONAS-AERUGINOSA AND PSEUDOMONAS-CEPACIA FROM CYSTIC-FIBROSIS PATIENTS [J].
BOSSO, JA ;
SAXON, BA ;
MATSEN, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :783-784
[3]  
BROOK I, 1989, REV INFECT DIS, V11, P361
[4]   METHODOLOGY FOR THE STUDY OF BETA-LACTAMASES [J].
BUSH, K ;
SYKES, RB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (01) :6-10
[5]   INVITRO ACTIVITY OF RO09-1428 COMPARED TO OTHER CEPHALOSPORINS [J].
CHIN, NX ;
GU, JW ;
FANG, W ;
NEU, HC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (08) :669-675
[6]   INVITRO ACTIVITY OF CEFPROZIL (BMY-28100) AND CEFEPIME (BMY-28142) AGAINST STREPTOCOCCUS-PNEUMONIAE, BRANHAMELLA-CATARRHALIS, AND HAEMOPHILUS-INFLUENZAE, AND PROVISIONAL INTERPRETIVE CRITERIA FOR DISK DIFFUSION AND DILUTION SUSCEPTIBILITY TESTS WITH HAEMOPHILUS-INFLUENZAE [J].
DOERN, GV ;
VAUTOUR, R .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1992, 15 (07) :633-640
[7]   INVITRO ACTIVITY OF CEFEPIME, A NEW PARENTERAL CEPHALOSPORIN, AGAINST RECENT EUROPEAN BLOOD ISOLATES AND IN COMPARISON WITH PIPERACILLIN TAZOBACTAM [J].
DORNBUSCH, K ;
MORTSELL, E ;
GORANSSON, E .
CHEMOTHERAPY, 1990, 36 (04) :259-267
[8]   EVALUATION OF THE INVITRO ACTIVITY OF BMY-28142, A NEW BROAD-SPECTRUM CEPHALOSPORIN [J].
FUCHS, PC ;
JONES, RN ;
BARRY, AL ;
THORNSBERRY, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (05) :679-682
[9]   ACTIVITY OF CEFEPIME AGAINST CEFTAZIDIME-RESISTANT AND CEFOTAXIME-RESISTANT GRAM-NEGATIVE BACTERIA AND ITS RELATIONSHIP TO BETA-LACTAMASE LEVELS [J].
FUNGTOMC, J ;
DOUGHERTY, TJ ;
DEORIO, FJ ;
SIMICHJACOBSON, V ;
KESSLER, RE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) :498-502
[10]   FREQUENCY OF INVITRO RESISTANCE OF PSEUDOMONAS-AERUGINOSA TO CEFEPIME, CEFTAZIDIME, AND CEFOTAXIME [J].
FUNGTOMC, J ;
HUCZKO, E ;
PEARCE, M ;
KESSLER, RE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (09) :1443-1445